1 / 2

PEGylated Protein Therapeutics Market Dynamics 2025

Due to the growth in demand for PEGylation, the rise in a number of chronic diseases, and the presence of strong pipeline drugs.

sandeeps88
Télécharger la présentation

PEGylated Protein Therapeutics Market Dynamics 2025

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PEGylated Protein Therapeutics Market - Global Opportunity Analysis and Industry Forecast, 2018-2025 PEGylation is a process of addition of active polyethylene glycol (PEG) to different forms of therapeutic proteins for chemical modification. These chemically modified therapeutic proteins are called PEGylated protein therapeutics. The chemical modification due to PEGylation results in various advantages, such as an extended half- life of a drug along with low toxicity and increased proteolytic protection, over the non- modified protein therapeutics. PEGylated protein therapeutics are used in multiple conditions such as cancer, hemophilia, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, and others. Download sample copy @ https://www.alliedmarketresearch.com/request- sample/3726 According to a new report published by Allied Market Research, titled, " PEGylated Protein Therapeutics Market by Product Type, Application, and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2018-2025, the market was valued at $10,388 million in 2017, and is projected to reach $17,813 million by 2025, growing at a CAGR of 6.9% from 2018 to 2025. North America is anticipated to be the highest revenue contributor throughout the forecast period. Major Players: • Amgen Inc. • AstraZeneca PLC • Biogen Inc. • F. Hoffmann-La Roche Ltd. (Genentech Inc.) • Horizon Pharma plc. • Leadiant Biosciences S.p.A. • Merck & Co.Inc. (Schering-Plough Corporation) • Pfizer Inc. • Shire plc (Baxalta) • UCB S.A. The factors that drive the growth of the global PEGylated protein therapeutics market are an increase in prevalence of chronic diseases, advantages offered by PEGylation, and strong presence of pipeline drugs are. However, high cost related to drug development and launch of generics during the forecast period is expected to impede the market growth.

  2. In addition, high market potential in the untapped emerging economies and increase in adoption of PEGylated protein therapeutics are expected to provide many opportunities during the forecast period. Key Benefits for Stakeholders: • This report entails a detailed quantitative analysis of the current market trends from 2017 to 2025 to identify the prevailing opportunities along with the strategic assessment of global PEGylated protein therapeutics market. • Market size and estimations are based on a comprehensive analysis of the applications and developments in the industry. • A qualitative analysis based on innovative products facilitates strategic business planning. • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the PEGylated protein therapeutics industry. Send enquiry us @ https://www.alliedmarketresearch.com/purchase-enquiry/3726

More Related